IDEXX Appoints Michael Erickson as CEO Effective May 12 2026, Chair Transition Planned

IDXXIDXX

IDEXX Laboratories will promote Michael (Mike) Erickson, PhD, to President and Chief Executive Officer effective May 12, 2026, while current CEO Jonathan Mazelsky transitions to Executive Chair and will retire after the May 2027 annual meeting. Erickson will also join the board to support an extended succession period.

1. IDEXX Expands Cancer Dx Panel with Mast Cell Tumor Testing

IDEXX will add mast cell tumor detection to its Cancer Dx Panel at no extra cost beginning mid-2026 in the United States and Canada, enabling screening of at-risk dogs (all dogs aged seven and older and high-risk breeds aged four and older). The panel, already used by more than 5,500 veterinary practices, detects lymphoma up to eight months before clinical signs and will now address over one-third of all canine cancer cases. Results will be delivered within 2–3 days in the U.S. (2–4 days in Canada) without altering specimen requirements or laboratory workflow, reinforcing IDEXX’s position in early, comprehensive veterinary oncology diagnostics.

2. IDEXX Unveils ImageVue DR50 Plus Low-Dose Imaging System

The ImageVue DR50 Plus Digital Imaging System, now available in the U.S. and Canada, reduces radiation exposure by up to 25% compared with the prior IDEXX DR50 model and by up to 60% versus competing veterinary systems. Featuring 14" x 17" and new 17" x 17" panels, AI-powered image optimization and automated protocols, the system minimizes retakes and accelerates diagnosis. Integrated with IDEXX Web PACS software—which automates hanging protocols and vertebral heart scoring—and direct submission to IDEXX Telemedicine Consultants (160+ board-certified specialists), the solution enhances workflow efficiency for practices where an estimated 75% of radiography technicians are women of childbearing age.

3. IDEXX Announces CEO Succession Plan

Effective May 12, 2026, Michael (Mike) Erickson, PhD, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become IDEXX President and Chief Executive Officer and join the Board. Jonathan (Jay) Mazelsky will transition to Executive Chair of the Board and will retire following the annual shareholders meeting in May 2027, ensuring an 12-month overlap to support a seamless leadership handoff. Erickson’s nearly two decades at IDEXX and prior strategy work at McKinsey underpin the Board’s confidence in his ability to drive long-term innovation and growth at the S&P 500 pet healthcare leader employing approximately 11,000 people worldwide.

Sources

BBB